INCY
INCYTE CORP
Nasdaq: INCY · Wilmington, DE · Healthcare
$96.22-0.70 (-0.72%)Closed
Market Cap$19.10B
Cash$3.38Bmost recent
Runwayprofitable
P/E (TTM)15.0EPS $6.41
52-Wk Range$57.38 – $110.57
Avg Volume1.9M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$96.22+85.3%
Pipeline

Drug candidates sponsored by INCYTE · ClinicalTrials.gov

45 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3ruxolitinib tablets
Polycythemia Vera
Completed
2014-01-15past
1
Phase 3pembrolizumab + epacadostat
Melanoma
Completed
2018-01-08past
1
Phase 3Ruxolitinib
Polycythemia Vera+10 more
Completed
2020-08-03past
10
Phase 3Ruxolitinib cream
Atopic Dermatitis+8 more
Recruiting
2026-08-10
13
Phase 3INCA034176
Chronic Graft-versus-host-disease
Recruiting
2027-09-28
1
Phase 3povorcitinib
Hidradenitis Suppurativa (HS)+1 more
Recruiting
2028-02-28
2
Phase 3INCB161734
Solid Tumors
Recruiting
2028-09-15
1
Phase 3parsaclisib
Myelofibrosis+8 more
Completed
2028-12-20
7
Phase 2INCB018424
Rheumatoid Arthritis
Completed
2008-09past
1
Phase 2INCB013739
Type 2 Diabetes
Completed
2009-04past
1
Phase 2Capecitabine
Pancreatic Cancer
Completed
2013-06past
1
Phase 1INCB047986
MDS (Myelodysplastic Syndrome)
Terminated
2014-09past
1
Phase 1INCB057643
Solid Tumors
Terminated
2019-02-13past
1
Phase 1INCAGN01949
Advanced Malignancies
Completed
2019-09-17past
1
Phase 2Ponatinib
Philadelphia Positive+2 more
Completed
2020-04-24past
1
Phase 1INCAGN01876
Advanced Malignancies+1 more
Terminated
2020-07-01past
1
Phase 1INCB001158
Relapsed or Refractory Multiple Myeloma+14 more
Completed
2022-11-28past
3
Phase 2INCB054707
Hidradenitis Suppurativa+3 more
Completed
2023-06-30past
4
Phase 2Ruxolitinib 1.5% cream
Vitiligo
Completed
2023-12-19past
1
Phase 1Pemigatinib
Lung Cancer+13 more
Completed
2024-04-11past
4
Phase 1INCB000928
Myelodysplastic Syndromes+2 more
Terminated
2024-08-15past
1
Phase 2Retifanlimab
Metastatic Non-small Cell Lung Cancer+9 more
Active, not recruiting
2026-04-14past
4
Phase 2Itacitinib
Plaque Psoriasis+14 more
Active, not recruiting
2026-06-22
11
Phase 2Axatilimab
Chronic Graft-versus-host-disease+2 more
Recruiting
2027-06-01
3
Phase 2Tafasitamab
Hematologic Malignancies+1 more
Recruiting
2027-08-29
2
Phase 2Dexelvucitabine
HIV Infections+1 more
Terminated—1
Phase 1INCB024360
Solid Tumors and Hematologic Malignancy
Completed
2013-05past
1
Phase 1Itacitinib (200 mg)
Graft-versus-host Disease (GVHD)
Completed
2016-06past
1
Phase 1INCB059872
Sickle Cell Disease
Terminated
2018-10-03past
1
Phase 1Pembrolizumab
Colorectal Cancer (CRC)+10 more
Completed
2019-11-07past
1
Phase 1INCB053914
Relapsed Diffuse Large B-Cell Lymphoma+1 more
Completed
2020-09-01past
1
Phase 1INCAGN02390
Cervical Cancer+20 more
Completed
2021-08-18past
1
Phase 1INCB086550
Healthy Volunteers+1 more
Completed
2023-11-17past
2
Phase 1INCB106385
Ovarian Cancer+10 more
Completed
2024-01-22past
1
Phase 1Ruxolitinib IR
Healthy Participants
Completed
2024-04-16past
1
Phase 1INCB 99280 with Ipilimumab
Melanoma+5 more
Terminated
2024-09-19past
1
Phase 1INCA00186
Advanced Solid Tumors+2 more
Terminated
2024-09-19past
1
Phase 1INCB099280
Healthy Participants+1 more
Completed
2025-04-11past
2
Phase 1INCB000631
Healthy Participants
Completed
2025-05-28past
1
Phase 1INCB081776
Advanced Solid Tumors
Terminated
2025-09-10past
1
Phase 1INCB040093
B-cell Malignancies
Active, not recruiting
2026-04-17past
1
Phase 1INCA033989
Healthy Participants+1 more
Recruiting
2026-05-23
2
N/AUnnamed
Chronic Myeloid Leukemia+3 more
Completed
2022-03-31past
1
N/AUnnamed
DLBCL - Diffuse Large B Cell Lymphoma
Recruiting
2025-06-30past
1
N/AUnnamed
Atopic Dermatitis+1 more
Completed
2025-12-19past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for INCY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.